James Nagarajah, MD, on the headline finding of BULLSEYE in HSPC | Urology Times

Trending on Urology Times

Inside the POTOMAC Trial: Durvalumab Plus BCG for High-Risk NMIBC

Radium-223 fails to improve skeletal event-free survival in metastatic RCC

Bringing POTOMAC Data Into Community Urology Practice for High-Risk NMIBC

POTOMAC Subgroup Data: Cystectomy Risk and Rare Adverse Events in NMIBC

FDA receives NDA submission for UGN-103 in recurrent LG-IR-NMIBC